Can HRT be personalized safely now?

According to current NAMS guidelines, HRT may be personalized for many women when prescribed and monitored by a clinician who assesses individual risk factors. Whether personalized HRT is appropriate depends on individual health factors that a prescriber should evaluate.

What personalization means now

Modern HRT allows a clinician to match the hormone, the dose, and the delivery method to a patient's symptoms, health history, and preferences. Current clinical practice includes the use of bioidentical hormones — hormones that are chemically identical to those produced by the ovaries. Both FDA-approved products (such as estradiol and micronized progesterone) and compounded preparations may contain bioidentical hormones. The term does not indicate superiority of one category over another. FDA-approved bioidentical hormones include estradiol patches, gels, sprays, pills, and vaginal options. Some patients may use compounded formulas when a dose or combination is not commercially available and when the compounding pharmacy meets quality standards. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

How clinicians personalize safely

• Health history guides selection: Clinicians assess migraines, blood pressure, clot history, breast health, uterus status, and family history to determine the most appropriate form.
• Route is carefully chosen: Per the Endocrine Society, transdermal estradiol (patch, gel, spray) has a lower thrombotic risk profile than oral formulations and avoids first-pass liver metabolism.
• Progesterone is tailored: According to ACOG, patients with an intact uterus typically require progesterone to protect the uterine lining. Per published clinical guidelines, micronized progesterone is generally well tolerated in most patients.
• Dose starts low: Per NAMS guidelines, clinicians typically start with the lowest effective dose and adjust based on symptom response.
• Monitoring is practical: Per FDA-approved prescribing information, follow-up is based on symptoms, blood pressure, and overall wellbeing. Routine blood hormone levels are not routinely required for monitoring.

Why personalization is safer now

According to current NAMS guidelines, current evidence provides clearer guidance on which forms are associated with lower risk, particularly regarding clotting and stroke. Per the Endocrine Society, transdermal estradiol and micronized progesterone have favorable safety profiles in published data for many women. For patients with complex medical histories, a prescriber can assess whether a particular form and dose may be appropriate based on their complete clinical picture.

Summary

Personalized HRT today involves a structured clinical process using well-studied hormones, careful individual assessment, and follow-up. Per published clinical guidelines, this approach may provide symptom relief in appropriate candidates when guided by a clinician who evaluates the patient's complete medical history. Whether personalized HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history.